Ionis Pharmaceuticals (IONS) Stock: Falls 2.23% Despite Roche’s Breakthrough Phase 3 Kidney Trial Results

TLDR IONS stock slides 2.23% to $42.93 despite Roche’s Phase 3 kidney trial success. Roche’s sefaxersen cuts proteinuria 43.1% in a key Phase 3 kidney disease trial. Ionis shares rebound 2.33% after hours to $43.93 following regular-session losses. Phase 3 data show stronger hematuria resolution with sefaxersen versus placebo. Roche targets regulators as its kidney [...]

The post Ionis Pharmaceuticals (IONS) Stock: Falls 2.23% Despite Roche’s Breakthrough Phase 3 Kidney Trial Results appeared first on Blockonomi.